Leen Jille, MPH, Public Health expert
Leen is a public health specialist with a focus on health systems, policy, global health and procurement and supply management, with more than 15 years of relevant work experience.
He has a broad range of expertise in strategic analysis, results and performance assessments, and different evaluation methods.
Leen worked in more than 25 countries in the Global South and lived in Nicaragua, the Democratic Republic of Congo, Ukraine and Mozambique.
On behalf of hera, he has led several projects for bilateral and multilateral agencies, Global Health Initiatives and NGOs.
Leen joined hera as a partner in 2014 as a Pharmaceutical procurement and supply chain management expert. He has been a Board member since 2018 and Board Chair from 2019 until early 2021 when he was elected hera’s Chief Executive Officer (CEO).
He is deeply embedded in hera’s culture, and as CEO, he is responsible for planning, implementing and integrating hera’s strategic direction.
Leen holds a master’s degree in public health (orientation Health Systems Management and Policy) from the Antwerp Institute of Tropical Medicine and a Certificate in Global Health Diplomacy from the State University of New York.
He is Dutch and fluent in English, French, Spanish and Portuguese.
Contact info: Leen.Jille@hera.eu
Related Stories
Read our latest post on the evaluation of the Norway-India Partnership Initiative (NIPI). Learn about the efforts of NIPI in providing support and fostering innovation in maternal, neonatal, and child health in India.
In 2023 hera was selected to undertake a critical review of the "Partnering for Transformational Change: Strengthening Liberia’s Surgical Health System" project. This initiative, implemented by Mercy Ships and funded by Norad, was established against the backdrop of Liberia's challenging healthcare environment, particularly in its surgical health system.
The World Health Organization (WHO), taking the lead in responding to this pressing issue, selected hera to conduct a study on the complexities of COVID-19 vaccine deployment and administration in humanitarian settings, with a specific focus on populations of concern (PoC). The study was initiated in March 2022 and concluded in March 2023, and encompassed case studies in multiple countries deeply affected by humanitarian crises: Cox's Bazar (Bangladesh), Colombia, the Democratic Republic of the Congo (DRC), Iraq, South Sudan, and Syria.
At the end of October this year, hera’s Director Marieke Devillé, CEO Leen Jille and Project Officer Alice Peschiutta made the trip to attend HSR2022 in Bogota, Colombia. By all accounts, it was an engaging experience and a positive immersion in health systems research.
The Norwegian agency for development cooperation (Norad) recently published a Country Evaluation Brief on the Democratic Republic of the Congo (DRC) prepared by a hera team of researchers.
Gavi, the Vaccine Alliance’s (Gavi’s) Fragility, Emergencies and Refugees (FER) policy has been in effect since June 2017.
MSF's Brussels supply chain aims to deliver critical medical supplies efficiently to complex areas. To assess its effectiveness, hera conducted an evaluation in 2021. This evaluation analyzed how well the supply chain met its goals, identified strengths and weaknesses, and provided recommendations for improvement, ultimately helping MSF optimize its life-saving operations.
A hera team, led by CEO Leen Jille and Associate Partner Giorgia Lattanzi, has been selected to support Health Systems Global (HSG) in developing its next 5-Year Strategic plan covering 2021-2026. The aim is to develop a strategic framework that continues to position HSG at “the forefront of health systems policy and research within the changing landscape of global health.”
UNICEF and USAID partnered with hera to improve healthcare procurement in Namibia. This collaboration aimed to deliver better value for money and improve health services at the community level. The project focused on identifying and addressing inefficiencies in the system. hera reviewed past analyses, facilitated dialogue between government ministries, and recommended versatile solutions.
hera's MTR evaluated implementation progress, identified challenges, and provided recommendations for improvement. The findings helped shape the subsequent CSP phase, emphasizing innovation and addressing key healthcare issues.
hera was selected to conduct the fourth external evaluation of the HRP covering the period from January 2013 to December 2017.
Assess the feasibility of the local production of essential medicines especially those related to the three communicable diseases, namely HIV and AIDS, TB and Malaria as well as the production of health commodities for the three diseases.